Company to highlight lead program CR-001, a tetravalent VEGF1
x PD-1 bispecific antibody in development for treating solid
tumors
WALTHAM,
Mass., Nov. 12, 2024 /PRNewswire/
-- Crescent Biopharma, Inc. ("Crescent"), a private
biotechnology company dedicated to advancing novel precision
engineered molecules targeting validated biology to advance care
for patients with solid tumors, announced management will present
at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am
EDT.
A live webcast of the presentation will be available at
https://wsw.com/webcast/jeff315/cresc/1987776. An archived
recording will be available for 90 days following the event.
In late October, Crescent entered into an acquisition agreement
with Rockville, Maryland-based
GlycoMimetics, Inc. (NASDAQ: GLYC). Following closing, the combined
company will operate under the name Crescent and advance its
portfolio of precision-engineered biologics to improve outcomes for
patients with solid tumors.
About Crescent Biopharma
Crescent Biopharma is a
biotechnology company dedicated to advancing novel precision
engineered molecules targeting validated biology to advance care
for patients with solid tumors. The company's pipeline of three
programs harnesses proven biology to accelerate the path to market
for potentially best-in-class therapeutics. For more information,
visit www.crescentbiopharma.com.
Media Contact:
Deerfield Group
Lia Dangelico
540-303-0180
lia.dangelico@deerfieldgroup.com
Investor Contact:
Argot Partners
Dawn Schottlandt
212-600-1902
dawn@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/crescent-biopharma-to-present-at-jefferies-london-healthcare-conference-2024-302301827.html
SOURCE Crescent Biopharma
